Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlunestrant and Abemaciclib in ER+ Breast Cancer with Minimal Residual Disease
NCT07191717Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- May 2026
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imlunestrant and abemaciclib in breast cancer, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Rate of circulating tumor deoxyribonucleic acid clearance. Started May 2026; status: recruiting.
02
Drugs
imlunestrantabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07191717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07191717.